Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of Day 2 (D2) once a cycle pegfilgrastim with Intermittent
Every Other Days of 5 Shot (D3-11) filgrastim in early breast cancer patients treated with
adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) regimen
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.